Blood-brain barrier in drug discovery : (Record no. 121962)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05614nam a2200469 i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC1895601 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240123070800.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 141015t20152015njuad ob 001 0 eng|d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118788356 (hardback) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118788547 |
| Qualifying information | (electronic bk.) |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC1895601 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL1895601 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr11005763 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaONFJC)MIL688522 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)899941813 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM315 |
| Item number | .B56 2015 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.7/8 |
| Edition number | 23 |
| 245 00 - TITLE STATEMENT | |
| Title | Blood-brain barrier in drug discovery : |
| Remainder of title | optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs / |
| Statement of responsibility, etc. | edited by Li Di, Edward H. Kerns. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hoboken, New Jersey : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons Inc., |
| Date of production, publication, distribution, manufacture, or copyright notice | [2015] |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2015 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (607 pages) : |
| Other physical details | illustrations (some color) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Source | rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Includes bibliographical references and index. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB - examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB - examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB - examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration - Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug - Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug - Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College). |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on print version record. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, MI : ProQuest, 2015. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Brain |
| General subdivision | Effect of drugs on. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Blood-brain barrier. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Di, Li, |
| Relator term | editor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kerns, Edward Harvel, |
| Relator term | editor. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Title | Blood-brain barrier in drug discovery : optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs. |
| Place, publisher, and date of publication | Hoboken, New Jersey : John Wiley & Sons Inc., [2015] |
| International Standard Book Number | 9781118788356 |
| Record control number | (DNLM)101643550 |
| -- | (DLC)11005763 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/bacm-ebooks/detail.action?docID=1895601">https://ebookcentral.proquest.com/lib/bacm-ebooks/detail.action?docID=1895601</a> |
| Public note | Click to View |
No items available.